Biphasic Material With PRF in Lateral Sinus Floor Augmentation

Maxillary Sinus Disease Clinical Trial

Official title:

The Lateral Approach Maxillary Sinus Floor Augmentation Using Biphasic Material Combined With Injectable Platelet Rich Fibrin- Randomized Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06071416
• Other study ID #: PRF in sinus augmentation
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: February 15, 2024
• Est. completion date: April 2024

Study information

• Verified date: January 2024
• Source: Assiut University
• Contact: Alzahraa Alghriany, Lecturer
• Phone: +201203770058
• Email: alghriany[@]aun.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A lack of bone in the posterior maxilla, mainly resulting from the combination of alveolar bone resorption after tooth loss, pneumatization of the maxillary sinus, and periodontal disease, leads to increased difficulty during dental implant treatment. The classic technique for maxillary sinus floor augmentation entails the preparation of the trap door to elevate the schneiderian membrane in the lateral sinus wall. it can be done either in a single stage with simultaneous implant placement or in two stages with delayed implant placement, depending on the available residual alveolar ridge height that necessary for implant primary stability. The new compartment created between the floor of maxillary sinus and the elevated membrane was filled with either autogenous, allografts, xenograft or combination of them to maintain space for new bone formation. The disadvantages of such methods are high costs for grafting material, time consuming and high morbidity, because harvesting of bone grafts is needed.

Description:

Recently, a systematic review demonstrated the effectiveness of synthetic bone materials, including biphasic calcium phosphate (BCP), as substitutes for autogenous bone. BCP consists of hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP). In contrast with stable HA, β-TCP is highly resorptive and is replaced by newly formed bone; therefore, the resorption rate of BCP could be influenced by the ratio of HA and β-TCP. platelet-rich fibrin (PRF) was recently introduced as additional or replacement materials in bone augmentation procedures. The use of biologic mediators with osteoinductive properties has been considered to reduce the time interval and accelerate the formation of new bone. The strengths of PRF in reducing tissue inflammation, promoting the vascularization of bone tissue, accelerating new bone formation, and improving scaffold mechanics have been reported.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 18
• Est. completion date: April 2024
• Est. primary completion date: March 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Residual bone crest height < 5 mm and width=6 mm in the planned implant site.
• Healed bone crest (at least 6 months elapsed from tooth loss/extraction);

Exclusion Criteria:

• Absolute medical contraindications to implant surgery such as uncontrolled diabetes mellitus, blood platelet disorders, serious osseous disorders, and cardiac arrhythmia; history of bone grafting in the posterior maxilla, immunocompromised patients, taking corticosteroids, taking aspirin before the procedure, positive history of chemotherapy and radiotherapy, and maxillary sinus pathologies

Related Conditions & MeSH terms

• Maxillary Sinus Disease
• Paranasal Sinus Diseases

Intervention

Procedure:
• Lateral sinus floor augmentation
maxillary sinus floor augmentation by lateral approach

Drug:
• Biphasic Calcium Phosphate
appliaction of BCP bone substitute

Procedure:
• Injectable platlets rich fibrin
centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vertical bone gain BG	Vertical bone gain (BG) 6 months after sinus augmentation in both height and density aspects by cone beam CT	6 months